Treatment and prevention of intraepithelial neoplasia

An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia

Joyce A. O'Shaughnessy, Gary J. Kelloff, Gary B. Gordon, Andrew J. Dannenberg, Ki Hong Waun, Carol J. Fabian, Caroline C. Sigman, Monica M. Bertagnolli, Steven P. Stratton, Stephen Lam, William G. Nelson, Frank L. Meyskens, David S. Alberts, Michele Follen, Anil K. Rustgi, Vali Papadimitrakopoulou, Peter T. Scardino, Adi F. Gazdar, Lee W. Wattenberg, Michael B. Sporn & 3 others Wael A. Sakr, Scott M. Lippman, Daniel D. Von Hoff

Research output: Contribution to journalArticle

310 Citations (Scopus)

Abstract

Precancer or intraepithelial neoplasia (IEN) is a noninvasive lesion that has genetic abnormalities, loss of cellular control functions, and some phenotypic characteristics of invasive cancer and that predicts for a substantial likelihood of developing invasive cancer. The AACR Task Force on the Treatment and prevention of IEN has delineated the relationship between IEN and cancer risk as well as the clinical benefit that can be derived from reducing IEN burden. Although several effective endoscopic and surgical treatments for IEN have become standard medical practice, these interventions can confer morbidity and do not treat the entire epithelial field at risk. The incidence of many epithelial cancers is continuing to rise, the number of individuals at risk is increasing with the aging population, and the rapid advancement of imaging and molecular diagnostics is bringing to light precancers that were heretofore clinically silent. There is therefore an urgent need to rapidly develop new treatment and prevention agents for IEN. The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions. The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer.

Original languageEnglish (US)
Pages (from-to)314-346
Number of pages33
JournalClinical Cancer Research
Volume8
Issue number2
StatePublished - 2002

Fingerprint

Advisory Committees
Research
Neoplasms
Therapeutics
Molecular Pathology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment and prevention of intraepithelial neoplasia : An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia. / O'Shaughnessy, Joyce A.; Kelloff, Gary J.; Gordon, Gary B.; Dannenberg, Andrew J.; Waun, Ki Hong; Fabian, Carol J.; Sigman, Caroline C.; Bertagnolli, Monica M.; Stratton, Steven P.; Lam, Stephen; Nelson, William G.; Meyskens, Frank L.; Alberts, David S.; Follen, Michele; Rustgi, Anil K.; Papadimitrakopoulou, Vali; Scardino, Peter T.; Gazdar, Adi F.; Wattenberg, Lee W.; Sporn, Michael B.; Sakr, Wael A.; Lippman, Scott M.; Von Hoff, Daniel D.

In: Clinical Cancer Research, Vol. 8, No. 2, 2002, p. 314-346.

Research output: Contribution to journalArticle

O'Shaughnessy, JA, Kelloff, GJ, Gordon, GB, Dannenberg, AJ, Waun, KH, Fabian, CJ, Sigman, CC, Bertagnolli, MM, Stratton, SP, Lam, S, Nelson, WG, Meyskens, FL, Alberts, DS, Follen, M, Rustgi, AK, Papadimitrakopoulou, V, Scardino, PT, Gazdar, AF, Wattenberg, LW, Sporn, MB, Sakr, WA, Lippman, SM & Von Hoff, DD 2002, 'Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia', Clinical Cancer Research, vol. 8, no. 2, pp. 314-346.
O'Shaughnessy, Joyce A. ; Kelloff, Gary J. ; Gordon, Gary B. ; Dannenberg, Andrew J. ; Waun, Ki Hong ; Fabian, Carol J. ; Sigman, Caroline C. ; Bertagnolli, Monica M. ; Stratton, Steven P. ; Lam, Stephen ; Nelson, William G. ; Meyskens, Frank L. ; Alberts, David S. ; Follen, Michele ; Rustgi, Anil K. ; Papadimitrakopoulou, Vali ; Scardino, Peter T. ; Gazdar, Adi F. ; Wattenberg, Lee W. ; Sporn, Michael B. ; Sakr, Wael A. ; Lippman, Scott M. ; Von Hoff, Daniel D. / Treatment and prevention of intraepithelial neoplasia : An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 2. pp. 314-346.
@article{6b860582fcbd4139b8f2ff33188b41a8,
title = "Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia",
abstract = "Precancer or intraepithelial neoplasia (IEN) is a noninvasive lesion that has genetic abnormalities, loss of cellular control functions, and some phenotypic characteristics of invasive cancer and that predicts for a substantial likelihood of developing invasive cancer. The AACR Task Force on the Treatment and prevention of IEN has delineated the relationship between IEN and cancer risk as well as the clinical benefit that can be derived from reducing IEN burden. Although several effective endoscopic and surgical treatments for IEN have become standard medical practice, these interventions can confer morbidity and do not treat the entire epithelial field at risk. The incidence of many epithelial cancers is continuing to rise, the number of individuals at risk is increasing with the aging population, and the rapid advancement of imaging and molecular diagnostics is bringing to light precancers that were heretofore clinically silent. There is therefore an urgent need to rapidly develop new treatment and prevention agents for IEN. The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions. The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer.",
author = "O'Shaughnessy, {Joyce A.} and Kelloff, {Gary J.} and Gordon, {Gary B.} and Dannenberg, {Andrew J.} and Waun, {Ki Hong} and Fabian, {Carol J.} and Sigman, {Caroline C.} and Bertagnolli, {Monica M.} and Stratton, {Steven P.} and Stephen Lam and Nelson, {William G.} and Meyskens, {Frank L.} and Alberts, {David S.} and Michele Follen and Rustgi, {Anil K.} and Vali Papadimitrakopoulou and Scardino, {Peter T.} and Gazdar, {Adi F.} and Wattenberg, {Lee W.} and Sporn, {Michael B.} and Sakr, {Wael A.} and Lippman, {Scott M.} and {Von Hoff}, {Daniel D.}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "314--346",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Treatment and prevention of intraepithelial neoplasia

T2 - An important target for accelerated new agent development: Recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia

AU - O'Shaughnessy, Joyce A.

AU - Kelloff, Gary J.

AU - Gordon, Gary B.

AU - Dannenberg, Andrew J.

AU - Waun, Ki Hong

AU - Fabian, Carol J.

AU - Sigman, Caroline C.

AU - Bertagnolli, Monica M.

AU - Stratton, Steven P.

AU - Lam, Stephen

AU - Nelson, William G.

AU - Meyskens, Frank L.

AU - Alberts, David S.

AU - Follen, Michele

AU - Rustgi, Anil K.

AU - Papadimitrakopoulou, Vali

AU - Scardino, Peter T.

AU - Gazdar, Adi F.

AU - Wattenberg, Lee W.

AU - Sporn, Michael B.

AU - Sakr, Wael A.

AU - Lippman, Scott M.

AU - Von Hoff, Daniel D.

PY - 2002

Y1 - 2002

N2 - Precancer or intraepithelial neoplasia (IEN) is a noninvasive lesion that has genetic abnormalities, loss of cellular control functions, and some phenotypic characteristics of invasive cancer and that predicts for a substantial likelihood of developing invasive cancer. The AACR Task Force on the Treatment and prevention of IEN has delineated the relationship between IEN and cancer risk as well as the clinical benefit that can be derived from reducing IEN burden. Although several effective endoscopic and surgical treatments for IEN have become standard medical practice, these interventions can confer morbidity and do not treat the entire epithelial field at risk. The incidence of many epithelial cancers is continuing to rise, the number of individuals at risk is increasing with the aging population, and the rapid advancement of imaging and molecular diagnostics is bringing to light precancers that were heretofore clinically silent. There is therefore an urgent need to rapidly develop new treatment and prevention agents for IEN. The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions. The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer.

AB - Precancer or intraepithelial neoplasia (IEN) is a noninvasive lesion that has genetic abnormalities, loss of cellular control functions, and some phenotypic characteristics of invasive cancer and that predicts for a substantial likelihood of developing invasive cancer. The AACR Task Force on the Treatment and prevention of IEN has delineated the relationship between IEN and cancer risk as well as the clinical benefit that can be derived from reducing IEN burden. Although several effective endoscopic and surgical treatments for IEN have become standard medical practice, these interventions can confer morbidity and do not treat the entire epithelial field at risk. The incidence of many epithelial cancers is continuing to rise, the number of individuals at risk is increasing with the aging population, and the rapid advancement of imaging and molecular diagnostics is bringing to light precancers that were heretofore clinically silent. There is therefore an urgent need to rapidly develop new treatment and prevention agents for IEN. The AACR IEN Task Force recommends focusing on established precancers as the target for new agent development because of the close association between dysplasia and invasive cancer and because a convincing reduction in IEN burden provides patient benefit by reducing cancer risk and/or by decreasing the need for invasive interventions. The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer.

UR - http://www.scopus.com/inward/record.url?scp=0036184605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036184605&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 314

EP - 346

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -